Manuel Schmidt

USPTO Granted Patents = 11 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 58(Granted Patents)

Company Filing History:

Gilead Sciences, Inc.

patents

1 out of 6

Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch

patents

where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11583581 - Methods of treating a retroviral infection (2023-02-21),

2. 11578331 - Combination comprising immunostimulatory oligonucleotides (2023-02-14),

3. 10604760 - Combination comprising immunostimulatory oligonucleotides (2020-03-31),

4. 10487333 - Combination comprising immunostimulatory oligonucleotides (2019-11-26),

5. 10006032 - Predictive biomarker for cancer therapy (2018-06-26),

6. 9499815 - Multimer for immunostimulation (2016-11-22),

7. 9375435 - Use of a DNA expression construct (2016-06-28),

8. 9345754 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2016-05-24),

9. 9212366 - Immune modulating oligonucleotides in connection with chemotherapeutic measures (2015-12-15),

10. 8017591 - Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals (2011-09-13),

11. 7635468 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine (2009-12-22),

Title: Manuel Schmidt: Innovator in Viral Infection Treatment

Introduction

Manuel Schmidt is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of viral infections. With a total of 11 patents to his name, Schmidt's work has the potential to impact the lives of many patients suffering from retroviral infections.

Latest Patents

One of Schmidt's latest patents focuses on methods of treating a retroviral infection. This invention relates to a non-coding sequence of deoxyribonucleic acids that includes at least one sequence motif NNCGNN. The sequence is designed for use in combination with antiretroviral therapy and/or histone de-acetylase inhibitors. Another notable patent involves a combination comprising immunostimulatory oligonucleotides, which provides a method for treating various diseases. This combination includes a T-cell regulator selected from a group of key proteins and a non-coding immunomodulating DNA.

Career Highlights

Throughout his career, Manuel Schmidt has worked with several notable companies, including Mologen AG and Gilead Sciences, Inc. His experience in these organizations has allowed him to develop innovative solutions in the medical field. Schmidt's dedication to research and development has positioned him as a leading figure in his area of expertise.

Collaborations

Schmidt has collaborated with esteemed colleagues such as Matthias Schroff and Burghardt Wittig. These partnerships have fostered an environment of innovation and have contributed to the advancement of his research.

Conclusion

Manuel Schmidt's contributions to the field of viral infection treatment through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for new therapeutic approaches that could benefit countless individuals.

This text is generated by artificial intelligence and may not be accurate.